Press Releases

Date Title and Summary View
Jun 23, 2011
MacroGenics Announces Presentation of Protégé Phase 3 Clinical Data at ADA in San Diego on June 28
ROCKVILLE, MD., June 23 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that 1-year data from Protégé, the Company’s Phase 3 clinical study of teplizumab in type
Additional Formats
Apr 28, 2011
Data Published in Blood Demonstrate Potent Activity of MacroGenics' Proprietary DART™ Technology
ROCKVILLE , MD. , April 28 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the publication in the journal Blood of preclinical data demonstrating potent
Additional Formats
Jan 06, 2011
MacroGenics Initiates Phase I Clinical Trial of MGAH22 for Patients with HER2-Expressing Solid Tumors
ROCKVILLE , MD. , January 6 /PRNewswire/ -- MacroGenics, Inc., a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that it had administered drug to the first cohort of patients in a Phase I clinical
Additional Formats
Oct 26, 2010
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics
Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics INGELHEIM, Germany and ROCKVILLE, MD, USA, October 26, 2010 -- Boehringer Ingelheim and MacroGenics today jointly announced that they have entered into a global
Additional Formats
Oct 26, 2010
MacroGenics Enters Global Research Collaboration and License Agreement with Pfizer
ROCKVILLE, MD, October 26, 2010 -- MacroGenics, Inc, a leader in next-generation antibody platforms and therapeutics, announced today that it has entered into a global research collaboration and license agreement with Pfizer Inc. to discover, develop and commercialize Dual-Affinity Re-Targeting
Additional Formats
Oct 20, 2010
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint
MacroGenics and Lilly Announce Pivotal Clinical Trial of Teplizumab Did Not Meet Primary Efficacy Endpoint ROCKVILLE, Md., INDIANAPOLIS, Ind. – Oct. 20, 2010 – MacroGenics, Inc. and Eli Lilly and Company (NYSE: LLY) today announced that the Protégé Data Monitoring Committee (DMC), composed of
Additional Formats
Jul 15, 2010
MacroGenics Receives NIH Grant Funding of $9.8M for Three Projects; Funding further Advances DART Platform and Infectious Disease Portfolio
ROCKVILLE, Md., July 15 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced that the National Institutes of Health (NIH) has awarded the company three new grants
Additional Formats
Jan 07, 2010
MacroGenics Appoints New Senior Vice President of Clinical Development
MacroGenics Appoints New Senior Vice President of Clinical Development ROCKVILLE , Md. , January 7 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment
Additional Formats
Jul 13, 2009
MacroGenics Announces the Initiation of a Phase 2 Clinical Trial to Evaluate the Safety and Efficacy of Monoclonal Antibody MGAWN1 in Subjects with Suspected Central Nervous System Infection Due to West Nile Virus
ROCKVILLE , Md. , July 13, 2009 /PRNewswire/ -- MacroGenics, Inc. today announced the initiation of the PARADIGM trial, a Phase 2 clinical study evaluating MGAWN1, a humanized monoclonal antibody, for the trea tment of individuals with suspected central nervous system infection due to West Nile
Additional Formats
Jun 23, 2009
Paulo F. Costa Joins MacroGenics Board of Directors
Paulo F. Costa Joins MacroGenics Board of Directors ROCKVILLE, MD., June 23, 2009 /PRNewswire/ -- MacroGenics, Inc. announced today that Mr. Paulo F. Costa has been elected to the company’s Board as an independent director. Mr. Costa is the former President and Chief Executive Officer of Novartis
Additional Formats
Jun 16, 2009
MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTÉGÉ, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes

Phase 3 PROTÉGÉ ENCORE Clinical Trial Initiated

Additional Formats
Mar 26, 2009
MacroGenics Appoints New Vice President of Business Development
MacroGenics Appoints New Vice President of Business Development ROCKVILLE, Md., March 26 /PRNewswire/ -- MacroGenics, Inc, a privately held biotechnology company that develops immunotherapeutics to treat autoimmune disorders, cancer and infectious diseases, today announced the appointment of Eric
Additional Formats
Sep 25, 2008
MacroGenics Raises $25M in Series D-2 Financing

Proceeds to be Used for Advancement of Cancer Stem Cells and Other Development Programs

Additional Formats
Jul 17, 2008
MacroGenics Acquires Raven Biotechnologies

Raven's Discovery Platform in Cancer Stem Cell Biology<br>Enhances MacroGenics' Oncology Capabilities and Complements Proprietary Antibody Technology Platforms

Additional Formats
May 06, 2008
Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer
Macrogenics Appoints New Chief Commercial Officer and Chief Financial Officer Rockville, Maryland.   May 6, 2008.  MacroGenics Inc, a private biotechnology company focused on the development of products to treat autoimmune disorders, cancers, and infectious diseases, today announced the
Additional Formats
Oct 18, 2007
Lilly and MacroGenics Announce Licensing and Collaboration Agreement

Lilly to Acquire Phase III Molecule Teplizumab for the Treatment of Type 1 Diabetes Companies to Collaborate on the Development of Autoimmune Disease Treatments

Additional Formats
Sep 26, 2007
Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman
Jeffrey H. Buchalter Joins Macrogenics Board of Directors as Chairman Rockville, MD.  September 26, 2007.  MacroGenics, Inc. announced today that Mr. Jeffrey H. Buchalter has been elected as Chairman of the company’s Board of Directors.  With more than 20 years of experience in product development
Additional Formats
Aug 02, 2007
Macrogenics Begins Global Phase 2/3 Protégé Study In Recent-onset Type 1 Diabetes Mellitus

Three Independent Clinical Trials Initiated with Teplizumab Manufactured at MacroGenics

Additional Formats
Jul 09, 2007
MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007
MacroGenics IND for West Nile Virus Monoclonal Antibody IS ACTIVE Phase 1 Clinical Trial to Commence in 2007 ROCKVILLE, MD.  July 9, 2007.  MacroGenics announced today that the companys investigational new drug (IND) application to the U.S. Food and Drug Administration for its monoclonal antibody
Additional Formats
Jan 03, 2007
MacroGenics and JDRF Form Partnership to Support Pivotal Phase II/III Clinical Trial of Anti-CD3 Monoclonal Antibody for Children and Adults with Recent-Onset Type 1 Diabetes

JDRF Provides MacroGenics with $2 Million in Funding for "Prot&#233;g&#233;" Trial

Additional Formats
Oct 16, 2006
MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors
MacroGenics Elects Industry Leader, Dr. John Maraganore, to Board of Directors Rockville , Maryland.  October 16, 2006.   MacroGenics, Inc., a privately-held immunotherapeutics company, announced today that John Maraganore, Ph.D., President and CEO of Alnylam Pharmaceuticals, has joined the
Additional Formats
Oct 10, 2006
MacroGenics Receives Orphan Drug Designation from FDA for Monoclonal Antibody to Treat Type 1 Diabetes

Pivotal Trial of CD3 Monoclonal Antibody to Begin in 2006

Additional Formats
Oct 05, 2006
MacroGenics Novel Monoclonal Antibody Shows Potent Anti-tumor Activity against B-Cell Lymphoma in Preclinical Studies

Newly Published Data Validate CD32B as Key Target in Non-Hodgkins Lymphoma

Additional Formats
Oct 02, 2006
MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs
MacroGenics receives multiple government awards totaling more than $62 million to advance infectious disease programs Rockville , Maryland, October 2, 2006  MacroGenics, Inc. announced today that the National Institute for Allergy and Infectious Diseases (NIAID), part of the National Institutes of
Additional Formats
May 17, 2006
MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs
MacroGenics Raises $45M in Series C Financing - Company to Advance Monoclonal Antibody Clinical Programs Rockville, MD, May 17, 2006  MacroGenics, Inc., a privately-held biotechnology company developing therapeutics for autoimmune disorders, cancer, and infectious diseases, today announced that it
Additional Formats